Enhancement of Proteasome Activity for the Treatment of Neurological Disorders

增强蛋白酶体活性治疗神经系统疾病

• 批准号: 8325007
• 负责人: Scott Michael Wilson
• 金额: $ 18.31万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8325007
• 关键词: Alzheimer' s Disease; Animal Model; Cell Nucleus; Cells; Chronic; Cytosol; Deubiquitinating Enzyme; Disease; Effectiveness; Frontotemporal Dementia; Genetic; Huntington Disease; Hydrolase; Lead; MJD1 protein; Medical; Mus; Mutant Strains Mice; Neurons; Parkinson Disease; Patients; Production; Proteasome Inhibitor; Proteins; Side; Spinocerebellar Ataxias; System; Transgenes; Ubiquitin; Work; cancer therapy; design; efficacy testing; improved; inhibitor/antagonist; intraperitoneal; mouse model; multicatalytic endopeptidase complex; mutant; nervous system disorder; novel; novel strategies; novel therapeutic intervention; protein TDP-43; protein aggregate; protein degradation; protein expression; protein misfolding; synuclein; tau Proteins; tau aggregation

DESCRIPTION (provided by applicant): While proteasome inhibitors are an effective cancer treatment option, the idea of accelerating the activity of the proteasome for medical purposes represents a novel treatment option for neurological disorders where harmful proteins accumulate and cause disease. Chronic neurological diseases such as Parkinson's, Alzheimer's, Huntington's, Frontotemporal dementia and Spinocerebellar ataxias are characterized by the presence of ubiquitinated protein aggregates and reduced proteasome function. Therefore, while these mutant proteins can be targeted for proteasomal degradation, they are not effectively eliminated by the ubiquitin proteasome system. We recently determined that either genetic or pharmacological inhibition of the ubiquitin hydrolase activity of Usp14 is sufficient to accelerate protein degradation by the proteasome. The levels of several proteins, including tau, TDP-43 and ataxin-3, were significantly decreased following the inhibition of Usp14's ubiquitin- hydrolase activity, indicating that Usp14 can function as an inhibitor of the proteasome. Our working hypothesis is that Usp14 functions to edit the ubiquitin side chains of proteins prior to their commitment to proteasomal degradation, resulting in release of the substrate from the proteasome. The focus of this proposal is to determine if loss of Usp14's ubiquitin hydrolase-activity can reduce the levels of aggregate- prone proteins produced in animal models of Huntington's disease, Frontotemporal dementia and Parkinson's disease. This novel approach to enhancing proteasome function for the clearance of aggregate- prone proteins may lead to a powerful new treatment option for patients suffering from chronic neurological diseases.

描述（由申请人提供）：虽然蛋白酶体抑制剂是一种有效的癌症治疗选择，但加速蛋白酶体为医学目的而活性的想法代表了神经系统疾病的新治疗选择，有害蛋白会积累并引起疾病。慢性神经系统疾病，例如帕金森氏症，阿尔茨海默氏症，亨廷顿，额颞痴呆和脊髓脑性疾病，其特征在于存在泛素化蛋白质聚集体和降低蛋白酶体功能。因此，尽管这些突变蛋白可以靶向蛋白酶体降解，但不会被泛素蛋白酶体系统有效消除。 我们最近确定，USP14的泛素水解酶活性的遗传学或药理抑制足以通过蛋白酶体加速蛋白质降解。在USP14的泛素水解酶活性抑制后，包括Tau，TDP-43和Ataxin-3在内的几种蛋白质的水平显着降低，表明USP14可以作为蛋白酶体的抑制剂起作用。我们的工作假设是USP14在承诺蛋白酶体降解之前编辑蛋白质的泛素侧链，从而导致底物从蛋白酶体中释放出来。该提案的重点是确定USP14的泛素水解酶活性的丧失是否可以降低亨廷顿氏病，额叶痴呆症和帕金森氏病的动物模型中产生的总体蛋白质水平。这种增强蛋白酶体功能以清除骨料蛋白的新方法可能会导致患有慢性神经系统疾病的患者有强大的新治疗选择。